AIMS: Heart rate was proposed as an emergent cardiovascular (CV) risk factor. Previous studies have shown associations between increased heart rate and CV risk in various populations. We aimed to evaluate the prognostic relevance of heart rate in a large contemporaneous medically optimized cohort of patients with stable chronic CV disease. METHODS AND RESULTS: In a post hoc analysis of the ONTARGET/TRANSCEND trials, we evaluated associations between baseline and average heart rate in trial with CV risk in 31, 531 patients followed for a median of 5 years. The primary outcome, major vascular events (MVE), was a composite of CV death, myocardial infarction (MI), stroke, and congestive heart failure (CHF). Pre-specified secondary outcomes included all-cause death and the individual components of the primary outcome. Associations between heart rate and outcomes were computed with heart rate as a continuous variable, baseline heart rate >70 vs ≤ 70 bpm, and across heart rate quintiles, adjusting for other markers of risk, beta-blocker and non-dihydropyridine calcium channel blocker use. For each 10 bpm increase in baseline and average heart rate, we observed a significant increase in risk of MVE, CV death, CHF and all-cause death. There was a continuous relationship between MVE and baseline and, more importantly, average in-trial heart rate, with no observed threshold. MVE, CV death, stroke, CHF, and all-cause death increased across heart rate quintiles. There was no association between MI and HR. Results were consistent in clinically relevant subgroups. There were modest but significant improvements in C-statistic and in statistical measures of model calibration for models that included heart rate for MVE, CV death, CHF and all-cause death. CONCLUSIONS: This large study examined and quantitated associations between heart rate and CV events in a contemporary medically optimized population with stable CV disease. Resting and, in particular, in-trial average heart rate are independently associated with significant increases in CV events and all-cause death.
RCT Entities:
AIMS: Heart rate was proposed as an emergent cardiovascular (CV) risk factor. Previous studies have shown associations between increased heart rate and CV risk in various populations. We aimed to evaluate the prognostic relevance of heart rate in a large contemporaneous medically optimized cohort of patients with stable chronic CV disease. METHODS AND RESULTS: In a post hoc analysis of the ONTARGET/TRANSCEND trials, we evaluated associations between baseline and average heart rate in trial with CV risk in 31, 531 patients followed for a median of 5 years. The primary outcome, major vascular events (MVE), was a composite of CV death, myocardial infarction (MI), stroke, and congestive heart failure (CHF). Pre-specified secondary outcomes included all-cause death and the individual components of the primary outcome. Associations between heart rate and outcomes were computed with heart rate as a continuous variable, baseline heart rate >70 vs ≤ 70 bpm, and across heart rate quintiles, adjusting for other markers of risk, beta-blocker and non-dihydropyridine calcium channel blocker use. For each 10 bpm increase in baseline and average heart rate, we observed a significant increase in risk of MVE, CV death, CHF and all-cause death. There was a continuous relationship between MVE and baseline and, more importantly, average in-trial heart rate, with no observed threshold. MVE, CV death, stroke, CHF, and all-cause death increased across heart rate quintiles. There was no association between MI and HR. Results were consistent in clinically relevant subgroups. There were modest but significant improvements in C-statistic and in statistical measures of model calibration for models that included heart rate for MVE, CV death, CHF and all-cause death. CONCLUSIONS: This large study examined and quantitated associations between heart rate and CV events in a contemporary medically optimized population with stable CV disease. Resting and, in particular, in-trial average heart rate are independently associated with significant increases in CV events and all-cause death.
Authors: Florian Custodis; Stephan H Schirmer; Magnus Baumhäkel; Gerd Heusch; Michael Böhm; Ulrich Laufs Journal: J Am Coll Cardiol Date: 2010-12-07 Impact factor: 24.094
Authors: Michael Böhm; Daniel Cotton; Lydia Foster; Florian Custodis; Ulrich Laufs; Ralph Sacco; Philip M W Bath; Salim Yusuf; Hans-Christoph Diener Journal: Eur Heart J Date: 2012-08-26 Impact factor: 29.983
Authors: Sripal Bangalore; Franz H Messerli; Fang-Shu Ou; Jacqueline Tamis-Holland; Angela Palazzo; Matthew T Roe; Mun K Hong; Eric D Peterson Journal: Eur Heart J Date: 2009-09-30 Impact factor: 29.983
Authors: S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight Journal: Lancet Date: 2008-08-29 Impact factor: 79.321
Authors: Jin Li; Jennifer Franke; Regina Pribe-Wolferts; Benjamin Meder; Philipp Ehlermann; Derliz Mereles; Florian Andre; Mohamed Assem Abdelrazek; Constanze Merten; Patrick A Schweizer; Rüdiger Becker; Hugo A Katus; Dierk Thomas Journal: Clin Res Cardiol Date: 2014-10-21 Impact factor: 5.460
Authors: Koki Nakanishi; Zhezhen Jin; Shunichi Homma; Mitchell S V Elkind; Tatjana Rundek; Seitetz C Lee; Aylin Tugcu; Mitsuhiro Yoshita; Charles DeCarli; Clinton B Wright; Ralph L Sacco; Marco R Di Tullio Journal: Stroke Date: 2017-12-28 Impact factor: 7.914
Authors: Buntaro Fujita; Marcus Franz; Bjoern Goebel; Michael Fritzenwanger; Hans R Figulla; Friedhelm Kuethe; Markus Ferrari; Christian Jung Journal: Clin Res Cardiol Date: 2012-03-28 Impact factor: 5.460
Authors: Wesley T O'Neal; Waqas T Qureshi; Suzanne E Judd; James F Meschia; Virginia J Howard; George Howard; Elsayed Z Soliman Journal: Int J Stroke Date: 2015-08-26 Impact factor: 5.266